Field performance evaluation of the PanBio rapid SARS-CoV-2 antigen assay in an
epidemic driven by 501Y.v2 (lineage B.1.351) in the Eastern Cape, South Africa
Oluwakemi Laguda Akingba <sup>a,b</sup> , Kaitlin Sprong <sup>a,b</sup> and Diana Ruth Hardie <sup>a,c</sup>
<sup>a</sup> National Health Laboratory Service, South Africa
<sup>b</sup> Department of Laboratory Medicine and Pathology, Faculty of Health Sciences, Walter
Sisulu University, Mthatha, South Africa
<sup>c</sup> Division of Medical Virology, Department of Pathology, University of Cape Town, Cape
Town, South Africa
word count: 1256
Corresponding author: Diana Hardie, C18 Laboratory, Groote Schuur Hospital, Anzio Rd
Observatory, 7925, Cape Town, South Africa
E mail: diana.hardie@uct.ac.za
Oluwakemi Laguda Akingba
e mail: <u>Oluwakemi.LA@nhls.ac.za</u>

- 19 Kaitlin Sprong
- 20 e mail: <u>Kaitlin.sprong@nhls.ac.za</u>
- 21

### 22

## 23 Abstract:

- 24 Background: South Africa was the African country most severely affected by the SARS-CoV-
- 25 2 pandemic during 2020, experiencing 2 waves of infection. During the first wave,
- 26 diagnostics were largely based on reverse transcription-linked PCR (RT-PCR). The Abbott
- 27 PanBio antigen test was deployed during the 2nd wave which was driven by emergence of
- the 501Y.v2 variant. At the time of evaluation in mid-November 2020, 501Y.v2 was the
- 29 dominant circulating virus in Nelson Mandela Bay, in the Eastern Cape Province.
- 30 Methods: A prospective diagnostic evaluation study was undertaken, during a period of
- high community transmission, to evaluate the field performance of the PanBio antigen RTD.
- 32 Testing was conducted at mobile community testing centres on 677 ambulant patients
- 33 seeking SARS-CoV-2 testing. RT-PCR was performed on the original naso-pharyngeal antigen
- 34 swabs to evaluate test performance.
- 35 Results: Of 146 RT-PCR positive individuals, 101 were RTD positive in the clinic. The antigen
- RTD had an overall sensitivity of 69.2% (95%CI 61.4, 75.8) and specificity of 99.0% (95%CI
- 37 98.8, 99.3) in this clinical context. Sensitivity was strongly dependent on the amount of
- virus in clinical samples, as reflected by the PCR cycle threshold (CT) value, with 100%
- detection in samples where the CT was <20, 96% with CT between 20-25, 89% with CT
- 40 between 26-30 and 64% when CT was 31-35.
- 41 Conclusions: The assay reliably detected 501Y.v2 infections in ambulatory ill patients. Assay
- 42 sensitivity was >90% in patients with high viral loads who are expected to be most
- 43 infectious. Negative and positive predictive values were also >90%.

# 44 Keywords:

- 45 SARS-CoV-2
- 46 501Y.v2
- 47 B.1.351
- 48 Rapid antigen test
- 49 Point of care

## 50 COVID-19

# 51 Abbreviations:

- 52 COVID-19. Coronavirus disease 2019; CT, cycle threshold; SARS-CoV-2, severe acute
- respiratory syndrome coronavirus 2; RTD, rapid test device; PCR, polymerase chain reaction;
- 54 RT-PCR, reverse transcription polymerase chain reaction; WHO, world health organisation;
- 55 501Y.v2, 501Y variant 2; IQR, interquartile range; NP, nasopharyngeal; GISAID, global
- 56 initiative for sharing all influenza data;

57

### 58

### 59 Background:

During 2020 South Africa was the African country most severely affected by the SARS-CoV-2 60 pandemic with more than 1 380 000 laboratory confirmed cases and 83 918 excess 61 62 deaths[1]. During this period, the country experienced 2 waves of infection[2]. Provision of an effective diagnostic service proved to be challenging. RT-PCR is the gold standard assay 63 for SARS-CoV-2 diagnosis, however, in the context of high disease prevalence, laboratory 64 systems may easily become overwhelmed. Rapid diagnostics such as antigen tests that can 65 be performed at point of care provide a welcome solution. Their main drawback is lower 66 sensitivity[3]. The WHO advises that assays that meet minimum performance requirements 67 (>80% sensitivity, >97% specificity in the first 7 days of symptoms) can be used in contexts 68 69 where nucleic acid-based testing is unavailable, or where turn-around times are 70 prolonged[4]. The Abbott PanBio rapid SARS-CoV-2 antigen assay has fulfilled these criteria in evaluations in several studies [5][6] 71 This assay was deployed during the 2<sup>nd</sup> wave in South Africa which first became apparent in 72 the Eastern Cape Province in October/November 2020. Increased disease activity was 73 associated with emergence of a new variant, namely 501Y.v2[7]. This variant, now referred 74 to as lineage B.1.351, first detected in October 2020 rapidly became the predominant virus, 75 across the country, due to its higher transmissibility[8]. At the time of evaluation in mid-76 77 November 2020, it was the dominant circulating virus, responsible for around 84% of infections in Nelson Mandela Bay, estimate based on genomes submitted to global initiative 78 for sharing all influenza data (GISAID) over this time period [9]. This prospective diagnostic 79

80 evaluation study was designed to evaluate the field performance of the PanBio assay, but

also provides evidence on its performance in individuals infected with 501Y.v2. Another

novel aspect to this study is that RT PCR was performed on the same swab used for antigen
testing, which obviated the need to collect further samples from patients and provided a

84 more direct comparison with the antigen result.

85 Methods and results:

- 86 Prospective diagnostic evaluation study in Nelson Mandela Bay municipality, Eastern Cape
- 87 South Africa during a period of high disease prevalence, using nasopharyngeal swabs to
- 88 determine the accuracy of Abbott PanBio COVID-19 antigen RTD.

## 89 Verifying that used antigen swabs were suitable for PCR:

- 90 44 paired swabs were collected from symptomatic patients, one nylon tip, standard issue
- swab for PCR and the flocked antigen swab from the PanBio test kit. SARSCoV-2 PCR was
- 92 done on used antigen and matched nylon swabs.
- 93 The used antigen swab was prepared for PCR as follows: 1 mL saline was added to the swab
- 94 container using a filter tip. The sample was vortexed and allowed to stand 2 minutes. The
- 95 bottom cap was opened and fluid bled into a sterile vial. The matching PCR swab was
- snipped into a vial containing 1.5 ml normal saline and vortexed.
- 97 Paired samples were extracted on the EasyMag (bioMerieux) platform. RT-PCR was done
- using the Seegene nCoV assay with amplification on BioRad CFX realTime PCR machine. For
- 99 PCR positive swabs, mean CT values of the 3 assay targets were compared.
- 100 Of the 44 paired samples, 13 were antigen positive. 26 were concordantly PCR negative,
- 101 one sample was PCR positive on the antigen swab, but negative on the regular swab and 17
- samples were concordantly PCR positive. When comparing mean CT values of the paired
- swabs, the antigen swab had values of 2 CTs lower than the swab collected for PCR.
- 104 Wilcoxon signed-rank test p0.0073. (figure 1)





106

Figure 1: Average CT values of PCR positive paired antigen vs regular swabs are compared: The 107 range of CT values from PCR of the antigen swab were on average 2 CTs lower than for those from 108 109 the standard swabs. Wilcoxon signed-rank test p0.0073.

#### 110 Study protocol:

111 Between 17 and 20 November 2020 mobile clinics ran community testing campaigns at 6

sites in Nelson Mandela Bay. Symptomatic patients were invited to undergo antigen testing. 112

Nasopharyngeal (NP) swabs were tested using the PanBio SARS-CoV-2 RTD. Results were 113

communicated to patients immediately. The used swabs were sent for PCR. RT-PCR: 114

Seegene nCoV assay (BioRad CFX platform) was performed on the same swab used for 115

116 antigen testing. (as described)

A total of 677 patients from 6 mobile clinics were tested by both antigen and PCR. Patients 117 were ambulant and seeking COVID testing. They ranged in age range from 3-85 years; 59% 118 were female. 119

Of these, 101 (14.9%) were antigen positive in the clinic. With PCR, 146 samples (21.4%) 120

were reported as positive, 19 (2.8%) as inconclusive (single target positive, CT>38) and 509 121

(75.2%) were negative for both tests. Inconclusive samples were excluded from analysis as 122

their significance was unresolved. 123

## 124 Antigen test performance:

- 125 Using PCR as the reference standard, the antigen test had an overall sensitivity (positive
- percent agreement) of 69.17% (95%CI 61.44, 75.80) and specificity (negative percent
- agreement) of 99.02% (95%CI 98.78, 99.26) in this clinical context.
- 128 Sensitivity was strongly dependent on the quantity of virus in clinical samples, as reflected
- by the CT value, with 100% detection by the antigen test in samples where the CT was <20,
- 130 95.5% with CT between 20-25, 89.3% with CT between 26-30 and 64,3% when CT was 31-35.
- 131 The CT values of antigen positive and negative samples are shown (Figures 2 a, b)
- 132 The antigen assay was positive in 3 PCR negative patients. Given the prevalence of infection
- of 21% (as determined by PCR) the predictive value of a negative test was 91.9% and that of



a positive test was 97.12%.





136

137 Figure 2 (a) Compares the number of antigen positive and negative samples according to CT

category values obtained in PCR, (b) Compares the percentage of antigen positive samples 138

139 according to virus levels, as reflected by the mean CT value.

140

#### **Characteristics of PCR positive samples:** 141

In the 146 PCR positive patients, CT values ranged from 17.4 to 41.3, median 30.1. 142 As

143 expected, the median CT and interquartile range (IQR) was lower in antigen positive samples

at 28.7 (IQR 25.3-31.3). In comparison, the median and IQR of CT of antigen negatives was 144

35.8 (IQR 32.7-37.1). (figure 3) 145

146



Figure 3: Compares the range of CT values obtained on antigen positive and negative samples by 148 149 reference PCR. Median and IQR values are given.

150

147

#### **Discussion:** 151

This study took place during a period of high community transmission associated with 152 emergence of the 501Y.v2 variant in the Eastern Cape. PCR was performed directly on the 153 antigen swab after testing which enabled a direct comparison to be made between antigen 154 reactivity and PCR on the same sample. Overall, the PanBio antigen test had a sensitivity of 155 69.17% and specificity of 99.0%. The sensitivity is below the 80% WHO benchmark[4]. 156 However, context is key. Testing was performed on unselected symptomatic individuals 157 158 who requested testing, irrespective of symptom duration. This probably accounts for the 159 fact that 50% of PCR positive patients had CT values > 30, indicating that on average sampling may have occurred later during infection than recommended for maximum 160 performance. Nonetheless performance was good in patients with CTs <30. In this range, 161 sensitivity was 91.3%. This concordance (using distinctly different technologies) suggests 162 that the 501Y.v2 was reliably detected by the RTD and at an expected level of frequency 163 when compared with PCR. 164

Assay specificity was similarly good at 99% and the predictive value of a positive test was
95%. This fulfils the WHO benchmark specificity requirements for deployment of this
assay[4].

168 2 factors could compromise detection of the 501Y.v2 variant; namely amino acid changes in

169 the region of the nucleocapsid protein targeted by kit antibodies, or reduced virus shedding

170 in respiratory tract samples. The higher infectivity of the variant makes the latter

explanation unlikely and preliminary evidence does not support it. 501Y.v2 has a single

amino acid change in the linker region of the nucleocapsid protein, namely N205I [9]. As

this amino acid is located in an unstructured region[10], it should not affect binding of kit

174 antibodies.

175 The main limitation was that it was not feasible to confirm 501Y.v2 infection in positive

176 cases. This was inferred from the fact that resurgence in this district was overwhelmingly

due to 501Y.v2, based on contemporaneous genomes submitted to GISAID [9].

178

### 179 **Conclusion:**

The assay reliably detected 501Y.v2 virus infection in ambulatory ill patients in this high prevalence community setting. Sensitivity was >90% in patients with high viral loads who are expected to be most infectious. To optimise the use of antigen RDTs in different and changing circumstances, clinical predictors and the epidemiological context should be considered when deciding how to deploy these assays.

185 **Ethics:** 

186 Ethical approval was obtained from the University of Cape Town Human Research Ethics Committee187 (UCT HREC 862.2020).

### 188 Informed consent:

Patients were willing participants and gave verbal consent to diagnostic testing. Data wasanonymised and delinked.

191 Author contributions:

192 Study concept and design: DH, OL

- 193 Conduct of study, sample testing: OL, KS
- 194 Manuscript write up: DH, OL, KS
- 195 All authors approved the final manuscript
- 196 **Declaration of competing interest:**
- 197 The authors report no competing interests.
- 198 Funding:
- 199 No funding was given for this study.
- 200 References:
- 201 [1] SAMRC, Report on Weekly Deaths in South Africa, South Africa
- 202 Med. Res. Counc. 2021 (2020) 1.
- 203 https://www.samrc.ac.za/reports/report-weekly-deaths-south-africa.
- 204 [2] L.B. Waasila Jassat1, Cheryl Cohen2, Caroline Mudara1, THE
- 205 FIRST AND SECOND WAVE OF COVID-19 IN THREE DISTRICTS OF
- 206 SOUTH AFRICA, COVID-19 Spec. PUBLIC Heal. Surveill. Bull.
- 207 COVID-19 Spec. PUBLIC Heal. Surveill. Bull. 18 (2021) 1–24.
- 208 [3] J. Cunningham, S. Beese, J. Dretzke, H. Im, P. Mj, H. Im, P. Mj, L.
- Hoo, L. Mmg, R. Spijker, V.D.B. A, diagnosis of SARS-CoV-2
- 210 infection ( Review ), (2020).
- https://doi.org/10.1002/14651858.CD013705.www.cochranelibr
   ary.com.
- [4] WHO, Antigen-detection in the diagnosis of SARS-CoV-2 infection
- using rapid immunoassays Interim guidance, 11 September
- 215 2020., World Heal. Organ. (2020).

# https://apps.who.int/iris/handle/10665/334253.

217	[5]	M. Linares, R. Pérez-Tanoira, A. Carrero, J. Romanyk, F. Pérez-
218		García, P. Gómez-Herruz, T. Arroyo, J. Cuadros, Panbio antigen
219		rapid test is reliable to diagnose SARS-CoV-2 infection in the first
220		7 days after the onset of symptoms, J. Clin. Virol. 133 (2020) 3–6.
221		https://doi.org/10.1016/j.jcv.2020.104659.
222	[6]	B. Mühlemann, M. Zuchowski, W. Karen, J. Lei, Comparison of
223		seven commercialSARS-CoV-2 rapid point of care antigen assays,
224		MedRxiv. (2020).
225		https://doi.org/https://doi.org/10.1101/2020.11.12.20230292.
226	[7]	H. Tegally, E. Wilkinson, M. Giovanetti, A. Iranzadeh, V. Fonseca,
227		J. Giandhari, D. Doolabh, S. Pillay, E.J. San, K. Wibmer, B.T.
228		Sewell, J. Lourenço, L. Carlos, J. Alcantara, S.L. Kosakovsky, S.
229		Weaver, D. Martin, R.J. Lessells, J.N. Bhiman, C. Williamson, T. De
230		Oliveira, Emergence and rapid spread of a new severe acute
231		respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage
232		with multiple spike mutations in South Africa, Arghavan
233		Alisoltani-Dehkordi. 10 (2020) 2020.12.21.20248640.
234		https://doi.org/10.1101/2020.12.21.20248640.
235	[8]	C.K. Wibmer, F. Ayres, T. Hermanus, M. Madzivhandila, SARS-
236		CoV-2 501Y . V2 escapes neutralization by South African COVID-
237		19 donor plasma, BioRxiv Prepr. (2021).

238		https://doi.org/https://doi.org/10.1101/2021.01.18.427166doi:
239	[9]	https://corona-maps.live/gisaid/
240	[10]	W. Zeng, G. Liu, H. Ma, D. Zhao, Y. Yang, M. Liu, Biochemica
241		characterisation of SARS-VoV-2 nucleocapsid protein, Biochem.
242		Biophys. Reearch Commun. 527 (2020) 618–623.
243		https://doi.org/https://doi.org/10.1016/j.bbrc.2020.04.136.
244		
245	Highli	ghts:
247	•	PanBio SARS-CoV-2 RTD performs well in a field evaluation with high disease
248		prevalence
249	•	Good concordance between RT-PCR and RTD in patients with 501Y.v2 variant
250		infection.
251	•	RT-PCR on the antigen swab enables a more direct comparison of methods.
252		